FINAL REPORT

Review of U.S. Customs and Border Protection's Fiscal Year 2023 Drug Control Budget Formulation Compliance Report
MEMORANDUM FOR: Troy A. Miller  
Senior Official Performing the Duties of the Commissioner  
U.S. Customs and Border Protection  

FROM: Joseph V. Cuffari, Ph.D. Inspector General  


Consistent with our responsibility under the Inspector General Act, we will provide copies of our report to congressional committees with oversight and appropriation responsibility over the Department of Homeland Security. We will post the report on our website for public dissemination.

Please contact me with any questions, or your staff may contact Kristen Bernard, Deputy Inspector General for Audits, at (202) 981-6000.

Attachment

OIG Project No. 23-060-AUD-CBP
January 23, 2024

Why We Did This Review

The Office of National Drug Control Policy (ONDCP) Circular, *National Drug Control Program Agency Compliance Reviews*, requires National Drug Control Program agencies to submit to the ONDCP Director by February 1 of each year a detailed accounting of all funds expended for National Drug Control Program activities during the previous fiscal year.

At least every 3 years, the Office of Inspector General is required to review the report and provide a conclusion about the reliability of each assertion made in the report.

What We Found


Based on its review, nothing came to Williams Adley’s attention that caused it to believe that CBP’s FY 2023 Budget Formulation Compliance Report and related assertions are not presented in conformity with the criteria in the ONDCP Circular. Williams Adley did not make any recommendations.

For Further Information:
Contact our Office of Public Affairs at (202) 981-6000, or email us at:
DHS-OIG.OfficePublicAffairs@oig.dhs.gov.
Independent Accountant’s Review Report

Inspector General
United States Department of Homeland Security

We have reviewed the accompanying Budget Formulation Compliance Report (BFCR) of the U.S. Department of Homeland Security’s (DHS) Customs and Border Protection (CBP) for the year ended September 30, 2023. CBP management is responsible for the preparation of the BFCR in conformity with the requirements of the Office of National Drug Control Policy Circular: National Drug Control Program Agency Compliance Reviews, dated September 9, 2021 (the Circular). Our responsibility is to express a conclusion about the BFCR based on our review.

Our review was conducted in accordance with the attestation standards established by the American Institute of Certified Public Accountants and generally accepted government auditing standards. Those standards require that we plan and perform the review to obtain limited assurance about whether any material modifications should be made to the BFCR or related assertions for them to be in accordance with the Circular. The procedures performed in a review vary in nature and timing from and are substantially less in extent than an examination, the objective of which is to obtain reasonable assurance about whether CBP’s BFCR and related assertions are in accordance with the Circular, in all material respects, in order to express an opinion. Because of the limited nature of the engagement, the level of the assurance obtained in a review is substantially lower than the assurance that would have been obtained had an examination been performed. We believe that the review evidence obtained is sufficient and appropriate to provide a reasonable basis for our conclusion.

We are required to be independent and to meet our other ethical responsibilities in accordance with relevant ethical requirements related to the engagement.

Among other requirements, the Circular requires CBP to submit its summer drug budget directly to the Office of National Drug Control Policy (ONDCP) at the same time its budget requests are provided to its agency heads. Based on our review, we determined CBP did not submit its summer drug budget to ONDCP directly. Rather, CBP submitted its summer drug budget to the DHS Budget Division Formulation Team for subsequent transmission to ONDCP. Although the process CBP utilized does not align to the Circular requirements, we are not modifying our conclusion because CBP’s assertion is accurate.

Based on our review, we are not aware of any material modifications that should be made to the BFCR or related assertions for the year ended September 30, 2023, in order for them to be in conformity with the requirements set forth in the Circular.
The purpose of this report is to authenticate the BFCR as required by the Circular based on our review and is not suitable for any other purpose. This report is intended solely for the information and use of DHS Office of Inspector General, CBP, and the ONDCP, and is not intended to be, and should not be, used by anyone other than the specified parties.

Washington, D.C.
January 17, 2024
January 17, 2024

Dr. Rahul Gupta  
Director  
Office of National Drug Control Policy  
Executive Office of the President  
Washington, DC 20503

Dear Dr. Gupta:

Enclosed is CBP’s FY 2023 Budget Formulation Compliance Report (BFCR) on National Drug Control Funding. In FY 2023, CBP reported enacted obligations of approximately $4,005.6 million.

If you have any questions or would like additional information, please contact me at (202) 325-4054.

Sincerely,

Jeffrey Caine  
Chief Financial Officer & Assistant Commissioner  
Office of Finance  
U.S. Customs and Border Protection  
Department of Homeland Security
U.S. DEPARTMENT OF HOMELAND SECURITY
U.S. CUSTOMS AND BORDER PROTECTION

Budget Formulation Compliance Report for Fiscal Year 2023 Drug Control Funds

BUDGET FORMULATION COMPLIANCE REPORT (BFCR)

A. Summer Budget Formulation Information

(1) Summer Drug Budget Transmittal

CBP’s Fiscal Year (FY) 2025 Summer Drug Budget Transmittal was provided to the Department of Homeland Security (DHS) Budget Office on July 3, 2023, for further transmission by DHS to ONDCP on July 3, 2023.

(2) Summary Table of Fiscal Year 2023 Summer Drug Control Obligations

<table>
<thead>
<tr>
<th>Drug Resources by Function</th>
<th>FY 2023 Enacted</th>
<th>President’s Budget</th>
<th>Summer Budget</th>
</tr>
</thead>
<tbody>
<tr>
<td>Intelligence</td>
<td>$603.092</td>
<td>$607.425</td>
<td>$629.530</td>
</tr>
<tr>
<td>Interdiction</td>
<td>$3,402.498</td>
<td>$3,747.203</td>
<td>$3,132.560</td>
</tr>
<tr>
<td><strong>Total Drug Resources by Function</strong></td>
<td><strong>$4,005.590</strong></td>
<td><strong>$4,354.628</strong></td>
<td><strong>$3,762.090</strong></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Drug Resources by Decision Unit</th>
<th>FY 2023 Enacted</th>
<th>President’s Budget</th>
<th>Summer Budget</th>
</tr>
</thead>
<tbody>
<tr>
<td>Operations and Support</td>
<td>$3,763.908</td>
<td>$3,865.777</td>
<td>$3,681.004</td>
</tr>
<tr>
<td>Border Security Operations</td>
<td>$1,113.714</td>
<td>$1,091.270</td>
<td>$824.3341</td>
</tr>
<tr>
<td>Trade and Travel Operations</td>
<td>$1,747.743</td>
<td>$1,815.894</td>
<td>$1,874.947</td>
</tr>
<tr>
<td>Integrated Operations</td>
<td>$850.607</td>
<td>$890.457</td>
<td>$927.613</td>
</tr>
<tr>
<td>Mission Support</td>
<td>$51.844</td>
<td>$68.156</td>
<td>$54.100</td>
</tr>
<tr>
<td>Procurement, Construction, and Improvements</td>
<td>$241.682</td>
<td>$488.851</td>
<td>$81.086</td>
</tr>
<tr>
<td>Border Security Operations</td>
<td>$105.139</td>
<td>$114.784</td>
<td>$9.810</td>
</tr>
<tr>
<td>Trade and Travel Operations</td>
<td>$59.634</td>
<td>$305.400</td>
<td>$0</td>
</tr>
<tr>
<td>Integrated Operations</td>
<td>$76.909</td>
<td>$68.667</td>
<td>$71.276</td>
</tr>
<tr>
<td><strong>Total Drug Resources by Decision Unit</strong></td>
<td><strong>$4,005.590</strong></td>
<td><strong>$4,354.628</strong></td>
<td><strong>$3,762.090</strong></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Drug Resources Personnel Summary</th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Total FTEs (direct only)</td>
<td>12,110</td>
<td>14,687</td>
<td>12,851</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Drug Resources as a Percent of Budget</th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Agency Budget (in Billions)</td>
<td>$20.86</td>
<td>$19.53</td>
<td>$19.65</td>
</tr>
<tr>
<td>Drug Resources Percentage</td>
<td>19.2%</td>
<td>22.3%</td>
<td>19.1%</td>
</tr>
</tbody>
</table>

---

1 To balance operational priorities vis-à-vis top line limitations, USCBP’s request of investment funds under the PC&I appropriation declined between FY 2024 and FY 2025.
B. Assertions

(1) Timeliness of Summer Budget Submission

CBP asserts that the FY 2025 Summer Drug Budget submitted to ONDCP was provided to the Department of Homeland Security (DHS) Budget Office, who then provided it to ONDCP on the same date as identified in the section above.

(2) Funding Levels Represent Bureau-Level Request

CBP asserts that the funding request in the FY 2025 Summer Drug Budget submission provided to ONDCP by the DHS Budge Office represents the funding levels in the budget submission made by CBP to DHS, without alteration or adjustment by any official at DHS.
Appendix A:
Report Distribution

**Department of Homeland Security**

Secretary
Deputy Secretary
Chief of Staff
Deputy Chiefs of Staff
General Counsel
Executive Secretary
Director, GAO/OIG Liaison Office
Under Secretary, Office of Strategy, Policy, and Plans
Assistant Secretary for Office of Public Affairs
Assistant Secretary for Office of Legislative Affairs

**U.S. Customs and Border Protection**

Commissioner
Chief Financial Officer
Audit Liaison
Chief Accountability Officer

**Office of Management and Budget**

Chief, Homeland Security Branch
DHS OIG Budget Examiner

**Congress**

Congressional Oversight and Appropriations Committees

**Office of National Drug Control Policy**

Associate Director for Management and Administration
Additional Information

To view this and any other DHS OIG reports, please visit our website: www.oig.dhs.gov

For further information or questions, please contact the DHS OIG Office of Public Affairs via email: DHS-OIG.OfficePublicAffairs@oig.dhs.gov

DHS OIG Hotline

To report fraud, waste, abuse, or criminal misconduct involving U.S. Department of Homeland Security programs, personnel, and funds, please visit: www.oig.dhs.gov/hotline

If you cannot access our website, please contact the hotline by phone or mail:

Call: 1-800-323-8603

U.S. Mail:
Department of Homeland Security
Office of Inspector General, Mail Stop 0305
Attention: Hotline
245 Murray Drive SW
Washington, DC 20528-0305